Streetbeat News

Price Targets

BAH

JP Morgan analyst Seth Seifman has maintained a Neutral rating on Booz Allen Hamilton (NYSE:BAH) and raised the price target from $120 to $136.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 2:54 pm

JNJ

Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Johnson & Johnson (JNJ) with a maintained price target of $215.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 2:52 pm

SMTI

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating on Sanara MedTech (NASDAQ:SMTI), with a maintained price target of $49.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 2:50 pm

ASND

Cantor Fitzgerald analyst Li Watsek maintains an Overweight rating on Ascendis Pharma (ASND) and raises the price target from $152 to $173.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 2:49 pm

EPD

Wells Fargo analyst Michael Blum has maintained an Overweight rating on Enterprise Prods Partners (EPD) and increased the price target from $31 to $32.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 2:47 pm

EL

Wells Fargo analyst Christopher Carey has maintained an Overweight rating on Estee Lauder Cos (NYSE:EL) and increased the price target from $155 to $175.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 2:45 pm

APD

Barclays analyst Michael Leithead has maintained an Equal-Weight rating on Air Products & Chemicals (APD) and reduced the price target from $260 to $245.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 2:40 pm

REGN

Cantor Fitzgerald analyst Olivia Brayer has maintained a Neutral rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and increased the price target from $850 to $925.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 2:39 pm

TKR

Goldman Sachs analyst Joe Ritchie maintains a Neutral rating on Timken (NYSE:TKR) and raises the price target from $78 to $87.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 2:38 pm

SYM

Goldman Sachs analyst Mark Delaney has maintained a Neutral rating on Symbotic (SYM) and reduced the price target from $51 to $44.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 2:37 pm